Literature DB >> 2374370

Atypical type III hyperlipoproteinemia in a patient with Ig A myelomatosis.

G Feussner1, E von Hodenberg, R Ziegler.   

Abstract

We studied a 58-year-old woman with severe therapy-refractory hyperlipidemia, xanthomatosis, and multiple myeloma (immunoglobulin A, lambda light chain). The lipid disorder became evident about half a year prior to the expression of myelomatosis. Clinical symptoms were similar to those found in classical type III hyperlipoproteinemia but the underlying metabolic defect was different from the one described in this primary dyslipoproteinemia. The patient has the heterozygous apolipoprotein E3/2 phenotype and her VLDL-cholesterol/serum-triglyceride ratio is unusually low at 0.05. Evidence is given that the hyperlipoproteinemia is due to an impaired catabolism of intermediate density lipoproteins probably because of a reduced hepatic triglyceride lipase activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2374370     DOI: 10.1007/bf01648250

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  38 in total

1.  Separation of plasma lipoproteins by density-gradient ultracentrifugation.

Authors:  T G Redgrave; D C Roberts; C E West
Journal:  Anal Biochem       Date:  1975-05-12       Impact factor: 3.365

2.  Autoimmune hyperlipidemia in a patient. Atherosclerotic course and chaning immunoglobulin pattern during 21 years of study.

Authors:  L A Lewis; V D deWolfe; A Butkus; I H Page
Journal:  Am J Med       Date:  1975-08       Impact factor: 4.965

3.  Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3.

Authors:  G R Warnick; C Mayfield; J J Albers; W R Hazzard
Journal:  Clin Chem       Date:  1979-02       Impact factor: 8.327

4.  Acquired type I hyperlipoproteinemia with systemic lupus erythematosus, dysglobulinemia and heparin resistance.

Authors:  C J Glueck; R I Levy; H I Glueck; H R Gralnick; H Greten; D S Fredrickson
Journal:  Am J Med       Date:  1969-08       Impact factor: 4.965

5.  Accumulation of intermediate density lipoprotein in plasma after intravenous administration of hepatic triglyceride lipase antibody in rats.

Authors:  T Murase; H Itakura
Journal:  Atherosclerosis       Date:  1981-06       Impact factor: 5.162

Review 6.  Antibodies against lipoproteins in man. Occurrence and biological significance.

Authors:  W Riesen; G Noseda
Journal:  Klin Wochenschr       Date:  1975-04-15

7.  Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia.

Authors:  A Corsini; P Roma; D Sommariva; R Fumagalli; A L Catapano
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

8.  Deficiency of hepatic lipase activity in post-heparin plasma in familial hyper-alpha-triglyceridemia.

Authors:  L A Carlson; L Holmquist; P Nilsson-Ehle
Journal:  Acta Med Scand       Date:  1986

9.  Cutaneous xanthoma in association with paraproteinemia in the absence of hyperlipidemia.

Authors:  K R Feingold; G R Castro; Y Ishikawa; P E Fielding; C J Fielding
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

10.  Interaction between fibroblasts, lipoproteins and three antilipoproteins IgA kappa.

Authors:  M F Baudet; C Dachet; J L Beaumont
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

View more
  1 in total

1.  Clinical features of type III hyperlipoproteinemia: analysis of 64 patients.

Authors:  G Feussner; A Wagner; B Kohl; R Ziegler
Journal:  Clin Investig       Date:  1993-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.